Comparison of 125I-JR11 Antagonist Binding with 125I-Tyr3-Octreotide Agonist Binding in Breast Cancer and RCCs Using 30,000 cpm/100 μL of Radioligand
| Tumor tissue | Surrounding vessels | |||
| Case no. | 125I-JR-11–specific binding (dpm/mg of tissue) | 125I-Tyr3-octreotide–specific binding (dpm/mg of tissue) | 125I-JR-11–specific binding (dpm/mg of tissue) | 125I-Tyr3-octreotide–specific binding (dpm/mg of tissue) |
| Breast cancer | ||||
| No. 1 | 3,648 | 394 | 4,632 | 1,465 |
| No. 2 | 2,179 het | 417 het | ||
| No. 3 | 283 | 0 | 1,861 | 508 |
| No. 4 | 9,937 | 1,535 | 4,302 | 0 |
| No. 5 | 1,891 het | 382 het | 2,497 | 0 |
| No. 6 | 881 | 0 | 2,062 | 0 |
| No. 7 | 4,226 het | 508 | ||
| No. 8 | 420 | 0 | 2,196 | 591 |
| No. 9 | 1,883 het | 0 | ||
| No. 10 | 0 | 0 | 2,236 | 0 |
| No. 11 | 8,788 | 958 | ||
| No. 12 | 9,225 | 1,349 | 3,325 | 559 |
| No. 13 | >10,000 | 1,207 | 3,512 | 0 |
| RCC | ||||
| No. 1 | 3,833 | 157 | ||
| No. 2 | 6,083 | 388 | ||
| No. 3 | 4,871 | 693 | 5,471 | 1,898 |
| No. 4 | 8,169 | 209 | ||
| No. 5 | 4,932 | 656 | ||
| No. 6 | 1,931 | 236 | 3,908 | 1,056 |
| No. 7 | 2,008 | 337 | 6,451 | 1,100 |
| No. 8 | 4,609 | 311 | ||
| No. 9 | 1,631 | 165 | 2,855 | 920 |
| No. 10 | 2,106 | 345 | 3,723 | 1,245 |
| No. 11 | 2,391 | 311 | 3,659 | 1,224 |
| No. 12 | 2,761 | 368 | 3,914 | 1,565 |
het = heterogeneous receptor distribution.
Nonspecific binding values measured in 13 breast carcinomas were 613 ± 73 dpm/mg of tissue (mean ± SEM) in 125I-JR11 experiments and 346 ± 24 dpm/mg of tissue in 125I-Tyr3-octreotide experiments. Nonspecific binding values in 12 RCCs were 397 ± 31 dpm/mg of tissue (mean ± SEM) in 125I-JR11 experiments and 270 ± 14 dpm/mg of tissue in the 125I-Tyr3-octreotide experiments.